🎤 Join our founder group to hear from firms like NEA on What it takes to raise a Series A?

Register
Doug Carlisle

Doug Carlisle

Partner Emeritus·Menlo Ventures

Portola Valley, California, USA

Bio

Professional summary

Doug Carlisle is Partner Emeritus at Menlo Ventures and has been with the firm since 1982, focusing on information technology investments. His current board seats and investments include nLight Photonics, Synthego, and Scality. His prior investments include Hotmail, IronPort Systems, Ansible, Kalpana, Pyxis, and Stratacom.

Notable companies

Selected portfolio companies the partner has backed

HotmailIronPort SystemsnLight PhotonicsSynthegoScality

Background

Career, education, and skills

Career history

  • Menlo VenturesPartner Emeritus1982 – Present

Education

  • University of California, BerkeleyBS, Electrical Engineering and Computer Sciences
  • Stanford UniversityJD/MBA

Other partners at Menlo Ventures

12 more profiles

Amy Wu Martin

Amy Wu Martin

Partner

Menlo Ventures

Amy Wu Martin is a Partner at Menlo Ventures focused on AI and consumer companies, with a background in consumer technology, gaming, blockchain, and digital media. She joined Menlo to grow its consumer technology and gaming practice.

ConsumerCrypto/web3Fintech
C.C. Gong

C.C. Gong

Principal

Menlo Ventures

Menlo principal investing in consumer tech, SaaS, and AI applications.

AIAI applicationsConsumer techEarly-stage startupsSaaS
Croom Beatty

Croom Beatty

Partner

Menlo Ventures

Croom Beatty is a Partner at Menlo Ventures focused on application-layer AI, fintech, healthcare IT, and vertical software. Since joining Menlo in 2017, he has led investments in companies including Arch, Finch, Manifest, NationGraph, Numeric, Prodigal, Rivet, Slash, Abacus, Accordance, Relcu, and Squad Health.

FintechGrowth-stage enterprise
Deborah Carrillo

Deborah Carrillo

General Counsel, Partner

Menlo Ventures

General Counsel and Partner overseeing legal, fund, deal, and compliance work at Menlo.

Corporate lawExit transactionsFund structuringRegulatory complianceVenture investments
Deedy Das

Deedy Das

Partner

Menlo Ventures

Early-stage AI, infrastructure, and enterprise software investor; ex-Glean, Google, and Facebook.

AI applicationsAI/MLEnterprise softwareInfrastructureSaaS
Derek Xiao

Derek Xiao

Principal

Menlo Ventures

Menlo principal backing AI, cloud infrastructure, and digital health startups.

AIBio + HealthcareCloud infrastructureDigital healthSaaS
Greg Yap

Greg Yap

Partner

Menlo Ventures

Greg Yap is a Partner at Menlo Ventures focused on life science, healthcare, and AI, with special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining Menlo in 2017, he has led investments including Cartwheel, Clear Labs, Curie, Delfi, Encoded, Genesis, H1, Ophelia, Particle, Pliant, Scribe, Vilya, and Xaira.

Bio + AIHealthcareLife sciences
Houman Haghighi

Houman Haghighi

Partner, Business & Corporate Development

Menlo Ventures

Business development partner helping Menlo portfolio companies scale through partnerships.

Business developmentCorporate partnershipsCustomer introductionsPortfolio growthStrategic financing
Ishika C.

Ishika C.

Investor

Menlo Ventures

Menlo investor focused on AI/ML, SaaS, and cloud infrastructure.

AI/MLCloud infrastructureConsumer internetSaaSSoftware infrastructure
Jean-Paul (J.P.) Sanday

Jean-Paul (J.P.) Sanday

Partner

Menlo Ventures

Inflection-stage investor focused on vertical SaaS, enterprise software, and future of work.

Data analyticsEnterprise softwareFuture of workInflection stageIntelligent automationVertical SaaS
Joff Redfern

Joff Redfern

Partner

Menlo Ventures

Joff Redfern is a partner at Menlo Ventures focused on software development workflows, AI-driven future-of-work products, and network-effect businesses including marketplaces.

ConsumerMarketplaces
Johnny Hu

Johnny Hu

Principal

Menlo Ventures

Menlo principal investing in biotech, life sciences, and novel therapeutics.

AIBio + HealthcareBiotechLife sciencesNovel therapeutics